These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 32923154)

  • 1. Surface-exposed and soluble calreticulin: conflicting biomarkers for cancer prognosis.
    Kepp O; Liu P; Zhao L; Plo I; Kroemer G
    Oncoimmunology; 2020 Jul; 9(1):1792037. PubMed ID: 32923154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secreted calreticulin mutants subvert anticancer immunosurveillance.
    Liu P; Zhao L; Kroemer G; Kepp O
    Oncoimmunology; 2020; 9(1):1708126. PubMed ID: 32002304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunosuppression by Mutated Calreticulin Released from Malignant Cells.
    Liu P; Zhao L; Loos F; Marty C; Xie W; Martins I; Lachkar S; Qu B; Waeckel-Énée E; Plo I; Vainchenker W; Perez F; Rodriguez D; López-Otin C; van Endert P; Zitvogel L; Kepp O; Kroemer G
    Mol Cell; 2020 Feb; 77(4):748-760.e9. PubMed ID: 31785928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interference of immunogenic chemotherapy by artificially controlled calreticulin secretion from tumor cells.
    Zhao L; Zhang S; Chen H; Kroemer G; Kepp O; Liu P
    Methods Cell Biol; 2022; 172():99-114. PubMed ID: 36064229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of calreticulin mutations in myeloproliferative neoplasms.
    Araki M; Komatsu N
    Int J Hematol; 2020 Feb; 111(2):200-205. PubMed ID: 31848992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calreticulin mutation does not contribute to disease progression in essential thrombocythemia by inhibiting phagocytosis.
    Daitoku S; Takenaka K; Yamauchi T; Yurino A; Jinnouchi F; Nunomura T; Eto T; Kamimura T; Higuchi M; Harada N; Saito N; Miyamoto T; Iwasaki H; Akashi K
    Exp Hematol; 2016 Sep; 44(9):817-825.e3. PubMed ID: 27185380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Development of myeloproliferative neoplasms by mutant calreticulin: underlying mechanisms].
    Araki M
    Rinsho Ketsueki; 2018; 59(8):1072-1077. PubMed ID: 30185708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calreticulin and cancer.
    Fucikova J; Spisek R; Kroemer G; Galluzzi L
    Cell Res; 2021 Jan; 31(1):5-16. PubMed ID: 32733014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant calreticulin interacts with MPL in the secretion pathway for activation on the cell surface.
    Masubuchi N; Araki M; Yang Y; Hayashi E; Imai M; Edahiro Y; Hironaka Y; Mizukami Y; Kihara Y; Takei H; Nudejima M; Koike M; Ohsaka A; Komatsu N
    Leukemia; 2020 Feb; 34(2):499-509. PubMed ID: 31462733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism underlying the development of myeloproliferative neoplasms through mutant calreticulin.
    Edahiro Y; Araki M; Komatsu N
    Cancer Sci; 2020 Aug; 111(8):2682-2688. PubMed ID: 32462673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel molecular mechanism of cellular transformation by a mutant molecular chaperone in myeloproliferative neoplasms.
    Araki M; Komatsu N
    Cancer Sci; 2017 Oct; 108(10):1907-1912. PubMed ID: 28741795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Checkpoint Blockade Enhances Shared Neoantigen-Induced T-cell Immunity Directed against Mutated Calreticulin in Myeloproliferative Neoplasms.
    Cimen Bozkus C; Roudko V; Finnigan JP; Mascarenhas J; Hoffman R; Iancu-Rubin C; Bhardwaj N
    Cancer Discov; 2019 Sep; 9(9):1192-1207. PubMed ID: 31266769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants.
    Chachoua I; Pecquet C; El-Khoury M; Nivarthi H; Albu RI; Marty C; Gryshkova V; Defour JP; Vertenoeil G; Ngo A; Koay A; Raslova H; Courtoy PJ; Choong ML; Plo I; Vainchenker W; Kralovics R; Constantinescu SN
    Blood; 2016 Mar; 127(10):1325-35. PubMed ID: 26668133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatic mutations of calreticulin in myeloproliferative neoplasms.
    Imai M; Araki M; Komatsu N
    Int J Hematol; 2017 Jun; 105(6):743-747. PubMed ID: 28470469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Calreticulin and Its Mutants on Endoplasmic Reticulum Function in Health and Disease.
    Arshad N; Cresswell P
    Prog Mol Subcell Biol; 2021; 59():163-180. PubMed ID: 34050866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation.
    Elf S; Abdelfattah NS; Chen E; Perales-Patón J; Rosen EA; Ko A; Peisker F; Florescu N; Giannini S; Wolach O; Morgan EA; Tothova Z; Losman JA; Schneider RK; Al-Shahrour F; Mullally A
    Cancer Discov; 2016 Apr; 6(4):368-81. PubMed ID: 26951227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion.
    Han L; Schubert C; Köhler J; Schemionek M; Isfort S; Brümmendorf TH; Koschmieder S; Chatain N
    J Hematol Oncol; 2016 May; 9(1):45. PubMed ID: 27177927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms.
    Araki M; Yang Y; Masubuchi N; Hironaka Y; Takei H; Morishita S; Mizukami Y; Kan S; Shirane S; Edahiro Y; Sunami Y; Ohsaka A; Komatsu N
    Blood; 2016 Mar; 127(10):1307-16. PubMed ID: 26817954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calreticulin mutations affect its chaperone function and perturb the glycoproteome.
    Schürch PM; Malinovska L; Hleihil M; Losa M; Hofstetter MC; Wildschut MHE; Lysenko V; Lakkaraju AKK; Maat CA; Benke D; Aguzzi A; Wollscheid B; Picotti P; Theocharides APA
    Cell Rep; 2022 Nov; 41(8):111689. PubMed ID: 36417879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutant specific anti calreticulin antibody (CAL2) immunohistochemistry as a screening test for calreticulin (CALR) mutation testing.
    Rahman K; Chandra D; Singh MK; Gupta R; Sharma A; Paul P; Kumar S; Sharma S; Nityanand S
    Int J Lab Hematol; 2020 Oct; 42(5):604-611. PubMed ID: 32463176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.